Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization
Open Access
- 3 August 2022
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 83, 104200
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLCJournal of Thoracic Oncology, 2017
- Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCJNCI: Journal of the National Cancer Institute, 2017
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsNature, 2016
- Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealedJournal of Structural Biology, 2015
- Lewis Lung Cancer Cells Promote SIGNR1(CD209b)‐Mediated Macrophages Polarization Induced by IL‐4 to Facilitate Immune EvasionJournal of Cellular Biochemistry, 2015
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015
- Macrophages and Therapeutic Resistance in CancerCancer Cell, 2015
- Macrophage plasticity and polarization: in vivo veritasJournal of Clinical Investigation, 2012